BioMedNewsBreaks

MondayAug 17, 2026 1:55 pm

BioMedNewsBreaks — Dyadic International, Inc. (NASDAQ: DYAI) Entered Agreements for $2.9 Million Registered Direct Offering and Private Placement 

Dyadic International (NASDAQ: DYAI) doing business as Dyadic Applied BioSolutions, entered into definitive agreements with an institutional investor for a registered direct offering of 3,625,000 common shares and a concurrent private placement of warrants to purchase 3,625,000 common shares. The common shares are priced at $0.795 each and the warrants at $0.005 each, with the warrants carrying an exercise price of $0.84 per share. Aggregate gross proceeds are expected to be approximately $2.9 million. The transactions are expected to close on or about Aug. 14, 2026, subject to customary closing conditions. Dyadic intends to use the net proceeds, together with existing cash, cash equivalents,…

Continue Reading

FridayAug 14, 2026 3:07 pm

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) Builds Foundation for Biomarker-Driven Cancer Therapy

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is advancing its precision oncology strategy through ONC010, a nanoparticle-encapsulated PNKP inhibitor being developed for biomarker-selected cancers. The company is building the manufacturing and scientific foundation needed to advance the program toward first-in-human studies, including polymer process development and analytical characterization activities with Nanosoft Polymers and metabolism studies through Nucro-Technics as part of its IND-enabling program. These efforts are designed to support scalable manufacturing, characterize ONC010’s metabolic profile and generate data for future pharmacokinetic, toxicology and regulatory activities. By combining targeted PNKP inhibition, nanoparticle…

Continue Reading

FridayAug 14, 2026 1:38 pm

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Builds Commercial Case for GelrinC in Multi-Billion Knee Cartilage Repair Market

Regentis Biomaterials (NYSE American: RGNT) was featured in a recent article highlighting the potential of its GelrinC cell-free hydrogel implant to address longstanding challenges in focal knee injuries through an off-the-shelf treatment designed to simplify surgical workflows, support faster recovery and promote durable tissue regeneration. The company recently received European regulatory approval for a next-generation, solvent-free manufacturing process that increases production yield by approximately 400%, supporting greater scalability and lower production costs. Regentis is also advancing surgeon training and European commercialization while progressing its pivotal U.S. Phase III SAGE trial, which is more than 50% enrolled. GelrinC’s combination of procedural simplicity, clinical…

Continue Reading

FridayAug 14, 2026 11:15 am

BioMedNewsBreaks – Gaxos.ai Inc. (NASDAQ: GXAI) Announces Warrant Exercise Expected to Generate $3.6 Million

Gaxos.ai (NASDAQ: GXAI) announced definitive agreements for the immediate exercise of outstanding warrants to purchase up to approximately 3.01 million shares of common stock at a reduced exercise price of $1.20 per share. The transaction is expected to generate approximately $3.6 million in gross proceeds before fees and expenses, with net proceeds intended for working capital and general corporate purposes. In consideration for the warrant exercise, Gaxos will issue new unregistered warrants to purchase up to approximately 6.02 million shares at an exercise price of $0.95 per share. The offering, for which H.C. Wainwright & Co. is serving as exclusive…

Continue Reading

FridayAug 14, 2026 9:50 am

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) reported second-quarter 2026 financial and operational results, including a 53% year-over-year reduction in operating expenses to $2.29 million and a 47% decrease in general and administrative expenses to $1.76 million. Combined cash, cash equivalents and digital assets totaled approximately $9.5 million as of June 30, up from $4.1 million at Dec. 31, 2025, with management stating that current liquidity is sufficient to fund planned operations to at least October 2027 assuming the first-half 2026 cash burn rate. Subsequent to…

Continue Reading

ThursdayAug 13, 2026 12:07 pm

BioMedNewsBreaks — Earth Science Tech, Inc. (OTC: ETST) Acquires Meduvo, Expands Pharmacy Network to 34 U.S. Jurisdictions

Earth Science Tech (OTC: ETST) announced the acquisition of Meduvo LLC, a compounding pharmacy based in La Verne, California, establishing a West Coast operational hub and expanding the company’s network to 34 U.S. jurisdictions. Meduvo currently operates from a 2,000-square-foot facility and compounds and dispenses non-sterile medications. ETST is initiating facility upgrades designed to meet sterility requirements, with management targeting full regulatory certification for sterile compounding by the end of 2028. The company said regulatory approvals are pending in additional states as it pursues nationwide coverage. To view the full press release, visit https://ibn.fm/dvo4H About Earth Science Tech, Inc. (ETST) Earth Science Tech, Inc. operates as a diversified holding company focused on the health and wellness sector.…

Continue Reading

ThursdayAug 13, 2026 9:50 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) CEO to Present at 2026 Georgia Life Sciences Summit

Nutriband (NASDAQ: NTRB) announced that CEO and Co-Founder Gareth Sheridan will present as part of the CEO Spotlight event at the 2026 Georgia Life Sciences Summit on Aug. 26. The summit, scheduled for Aug. 25-26 at the Sandy Springs Performing Arts Centre in Sandy Springs, Georgia, brings together leaders across biotechnology, medical technology, research, manufacturing and investment. Nutriband is developing AVERSA (TM), its abuse-deterrent transdermal technology designed to incorporate aversive agents into patches to help prevent abuse, diversion, misuse and accidental exposure involving drugs with abuse potential. To view the full press release, visit https://ibn.fm/Un3ax About Nutriband Inc. We are primarily…

Continue Reading

WednesdayAug 12, 2026 12:02 pm

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Reports Strong Correlation for Finger-Prick Nu.Q NETs Prototype in Sepsis Patients 

VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, announced that results using its lateral flow finger-prick prototype were highly correlated with results from its established automated Nu.Q NETs test in critically ill sepsis patients, supporting the potential expansion of nucleosome testing beyond centralized laboratories. The company said the lateral flow test could enable rapid identification of high-risk patients in emergency rooms or at the bedside, with testing showing a Spearman correlation of 0.85 and Pearson correlation of 0.881 compared with its CE-marked laboratory assay. The study, part of the SUMMIT program, evaluated capillary blood and plasma samples from intensive care patients and demonstrated significant correlation between…

Continue Reading

TuesdayAug 11, 2026 2:57 pm

BioMedNewsBreaks — Nano-X Imaging Ltd. (NASDAQ: NNOX) Optimizes Nanox.AI Medical Imaging Framework for Intel Core Ultra Processors 

Nano-X Imaging Ltd. (NASDAQ: NNOX) announced that subsidiary Nanox AI Ltd. has optimized its medical imaging AI application framework for Intel Core Ultra processors using Intel OpenVINO toolkit. The framework is designed to enable healthcare facilities to evaluate and deploy CT imaging AI applications on on-premise edge devices while keeping imaging data within their own infrastructure. Nanox.AI solutions analyze routine CT scans to help identify findings correlated with chronic conditions involving cardiac, liver and bone health. The optimized framework successfully ran inference on Intel Core Ultra-class hardware using OpenVINO, demonstrating its suitability for on-premise medical imaging AI processing. Nanox.AI said the approach can bring AI-enabled imaging insights closer to the point of care, while local edge inference…

Continue Reading

TuesdayAug 11, 2026 1:35 pm

BioMedNewsBreaks — AOM Capital Completes $5.1 Million Financing for Therapeutics Company Acquisition 

AOM Capital announced the completion of a $5.1 million financing for a therapeutics company in connection with its acquisition of a pharmaceutical drug asset. The private investment and specialty bridge lending firm structured the financing around the specific requirements of the transaction, providing the capital needed to support the acquisition. AOM Capital said the transaction expands its activity in private credit, acquisition financing and special situations, with the firm focused on providing flexible capital for acquisitions, bridge transactions, growth initiatives and other complex or time-sensitive opportunities. To view the full press release, visit https://ibn.fm/imbdB About AOM Capital AOM Capital is a private investment and specialty bridge…

Continue Reading